OBJECTIVES:  The aim of our study is to analyze the public price of the montelukast sodium therapy in Hungary within the generic competition. METHODS:  Data derived from the nationwide pharmaceutical database of Hungarian National Health Insurance Fund Administration. We analízes the annual turnover and price of the medicaments containing the active substance montelukast sodium from 2007 to 2015. Accordingly our indicators were: consumer price, DCT (Daily cost of Therapy), co-payment, quasi co-payment, DOT (Days of Treatment). RESULTS:  Before the appearance of generic medicaments (October, 2011), the public price of the brand-name Singulair 10 mg tablets was 7 USD (on lifted category legal title). Due to the blind bid methods of the Hungarian National Health Insurance Fund Administration the public price of Singulair decreased to 1.5 USD in January, 2013. The public price of the generic drugs started from about 2 USD (October, 2011) and decreased to about 0.7 USD (April, 2013). Due to the increasing DOT the total amount of the public price payed by the patients had increased until 2011, it reached the amount of 1 million USD, then due to the generic competition and blind bid methods it decreased to 490.000 USD. The total amount of public price of the brand-name Singulair moved to the generics during 3 years (2011-2014). The DCT of the originator Singulair 10 mg tablets decreased from 1.1 USD to 0.34 USD, the DCT of the generic product Montelukast TEVA decreased from 0.67 USD to 0.16 USD in the period under review. CONCLUSIONS:  Due to the generic competition the patients’ access to drugs containing montelukast sodium increased significantly.